Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG0908 biweekly R-CHOP vs biweekly R-CHOP followed by CHASER before LEED and autologous stem-cell transplantation in poor-risk DLBCL
jRCTs031180103Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in diffuse large B-cell lymphoma (DLBCL), lymphomatoid granulomatosis (LYG) and primary mediastinal large B-cell lymphoma (PMBCL) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 2-year progression-free survival rate. Started Sep 2010; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)lymphomatoid granulomatosis (LYG)primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on jRCTs031180103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180103.